Previous close | 12.25 |
Open | 12.25 |
Bid | 9.60 |
Ask | 14.00 |
Strike | 26.00 |
Expiry date | 2024-06-21 |
Day's range | 12.25 - 12.25 |
Contract range | N/A |
Volume | |
Open interest | 27 |
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. Details of the company’s participation are as follows: Goldman Sachs 45th Annual Gl
Insights into RVMD's Financial Health and Future Directions
Revolution Medicines ( NASDAQ:RVMD ) First Quarter 2024 Results Key Financial Results Net loss: US$116.0m (loss widened...